يحاول ذهب - حر
Gavi inks agreement with Moderna for COVID-19 vaccine supply to LICs
November 2022
|BioSpectrum Asia
Gavi, the Vaccine Alliance, has signed an agreement with Moderna related to the supply of COVID-19 vaccines to lower-income countries (LICs) supported by the Gavi COVAX Advance Market Commitment (AMC).
-
Under the agreement, Gavi and Moderna agree to cancel remaining volumes under their previous agreement in 2022, and establish a framework for LICs to access doses of variant-containing vaccine (VCV) beginning in 2023. Gavi will have the right to access up to 100 million VCV doses, at Mode
هذه القصة من طبعة November 2022 من BioSpectrum Asia.
اشترك في Magzter GOLD للوصول إلى آلاف القصص المتميزة المنسقة، وأكثر من 9000 مجلة وصحيفة.
هل أنت مشترك بالفعل؟ تسجيل الدخول
المزيد من القصص من BioSpectrum Asia
BioSpectrum Asia
Vietnam Rises as a Key Pharmerging Market
Vietnam is emerging as one of Asia's most promising pharmaceutical and biotechnology markets. As the government advances its national pharma strategy and regional collaborations deepen, the country is positioning itself as a future hub for biotech in Southeast Asia. We look at how the key trends are shaping Vietnam's pharma and biotech sectors from regulatory reforms and investment flows to the rise of local innovators.
4 mins
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Mind Over Matter: Decoding China's BCI Push
Once popularised by Elon Musk's Neuralink, brain-computer interface (BCI) technology is now drawing major interest in China. We now look at how the country is stepping up research and investment to advance its own BCI ecosystem.
6 mins
BioSpectrum Asia Nov 2025
BioSpectrum Asia
"GST reduction makes diagnostics more accessible and supports “Make in India” vision by levelling the field for local products"
The Association of Diagnostics Manufacturers of India (ADMI), the apex body representing 80-90 domestic and multinational in vitro diagnostics (IVD) companies, has announced the election of Jatin Mahajan, Managing Director of J. Mitra & Co., as its new President recently. Under his leadership, ADMI aims to foster greater collaboration between Indian firms and global players through inclusive working groups and open forums. By presenting a unified industry voice, the association plans to engage policymakers and regulators more effectively, advocating for regulatory reforms, quality standards, tax rationalization, and other supportive policies. In an interaction with BioSpectrum Asia Mahajan emphasizes that aligning perspectives across the sector will not only ensure a level playing field but also drive sustainable growth, strengthen India's diagnostics ecosystem, and enhance its global competitiveness. Edited excerpts;
7 mins
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Political will, investment in surveillance and health systems against AMR
Antimicrobial Resistance (AMR) dominated discussions at the Seventy-eighth session of the World Health Organization (WHO) South-East Asia Regional Committee, held from October 13–15 in Colombo. Member States adopted a major resolution to strengthen national responses to AMR, coinciding with the release of WHO's Global Antimicrobial Resistance Surveillance Report 2025, which warns of growing global resistance to essential antibiotics. The new WHO report, launched on October 13, presents the most comprehensive analysis to date of antibiotic resistance trends worldwide. Based on data reported by over 100 countries through the WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS), it found that one in six bacterial infections globally in 2023 was resistant to common antibiotic treatments. Between 2018 and 2023, resistance increased in over 40 per cent of pathogen-antibiotic combinations, with annual rises of 5–15 per cent.
2 mins
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Thailand's Life Sciences Push Gains Business Momentum
Thailand, emerging as a life sciences hub, fueled by biotech startups, multinational investment, and government-backed research in vaccines, genomics, and regenerative medicine, is positioning itself as ASEAN’s leading center for healthcare innovation.
2 mins
BioSpectrum Asia Nov 2025
BioSpectrum Asia
'Point of care will change the CDMO business structure from Centralised to De-Centralised cell manufacturing”
With Japan emerging as a hub for regenerative medicine innovation, Teijin Regenet—a Teijin Group company— has become a key player driving next-generation manufacturing and CDMO growth.
2 mins
BioSpectrum Asia Nov 2025
BioSpectrum Asia
EXPEDITING APPROVALS OF SAFE & AFFORDABLE BIOSIMILARS
While the world is discussing and troubled over 100 per cent tariffs on medicines announced just over a month back by the US administration, there is a music played to the ear of pharma producers in Asia. This music was played by the US Food and Drug Administration (FDA) last week when it made a major announcement over approvals of biosimilars, generic versions of complex biological drugs, that treat serious and chronic diseases.
2 mins
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Policy Reforms Give India's MedTech Sector a Global Edge
Since medical technology (MedTech) is a sunrise industry, the government is giving it priority to support patient-centric growth, while also concentrating on lowering reliance on imports and aligning regulations with international norms. With a focus on capital, incubation, talent development, and market access, the Indian government has started a broad range of programmes to support MedTech firms. This article examines governmental and regulatory efforts, emphasizing how policy-driven assistance is helping MedTech businesses become more globally competitive.
6 mins
BioSpectrum Asia Nov 2025
BioSpectrum Asia
The Zika Comeback: One Vaccine, One Hope
Asia, the epicenter of flaviviruses like Japanese encephalitis (JE), dengue, and Zika, faces both a critical need and a strategic opportunity to lead vaccine development. Phylogenetic evidence shows that the Zika strain behind the Americas outbreak originated in Southeast Asia. With global pipelines favouring high-income markets, regional biotech can drive preventive solutions, scale production, and avert outbreaks as Zika quietly resurfaces across Southeast Asia.
4 mins
BioSpectrum Asia Nov 2025
BioSpectrum Asia
India signs MoU with Pfizer to strengthen healthcare innovation ecosystem
In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, Government of India, has signed a Memorandum of Understanding (MoU) with US-based Pfizer Limited.
1 min
BioSpectrum Asia Oct 2025
Translate
Change font size